Somatostatin Receptor-Targeted Radiopeptide Therapy in Treatment-Refractory Meningioma: Individual Patient Data Meta-analysis

Conclusion: To our knowledge, this individual patient data meta-analysis represents the most comprehensive analysis of the benefits of and adverse events associated with SSTR-targeted PRRT for treatment-refractory meningioma. The treatment was well tolerated, achieved disease control in most cases, and showed promising results regarding PFS and OS.

Source: Journal of Nuclear Medicine - March 29, 2021 Category: Nuclear Medicine Authors: Mirian, C., Duun-Henriksen, A. K., Maier, A., Pedersen, M. M., Jensen, L. R., Bashir, A., Graillon, T., Hrachova, M., Bota, D., van Essen, M., Spanjol, P., Kreis, C., Law, I., Broholm, H., Poulsgaard, L., Fugleholm, K., Ziebell, M., Munch, T., Walter, M. Tags: Clinical Source Type: research